LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Preterm Birth Clues Identified in Cervicovaginal Microbiome

By LabMedica International staff writers
Posted on 03 Apr 2019
Print article
Image: The HiSeq 2500 System is a powerful high-throughput sequencing system (Photo courtesy of Illumina).
Image: The HiSeq 2500 System is a powerful high-throughput sequencing system (Photo courtesy of Illumina).
Failure to predict and understand the causes of preterm birth, the leading cause of neonatal morbidity and mortality, have limited effective interventions and therapeutics. Preterm birth (PTB) is defined as birth before 37 completed weeks of gestation and is the leading cause of death in neonates and children under the age of 5.

The interaction between microbial communities and their host, in many biological niches, has been found to be mechanistically involved in health and disease pathogenesis. There have been only a few studies that have examined the relationship between cervicovaginal microbial communities and spontaneous preterm birth.

A group of scientists collaborating with the University of Maryland School of Medicine (Baltimore, MD, USA) enrolled within 2,000 pregnant women, and identified a few hundred women for a nested case-control study of spontaneous preterm birth (sPTB), a group that included 107 extensively phenotyped women who gave birth prior to 37 weeks of gestation and 432 unaffected women who delivered their babies at term. Nearly three-quarters of the participants were African-American, and the median age of the mothers was 28 years old. The investigators had access to cervicovaginal swab samples and anthropometric measurements collected at three points during pregnancy: at 16 to 20 weeks gestation, 20 to 24 weeks gestation, and between 24 and 28 weeks gestation.

Amplicons were visualized on a 2% agarose gel, quantified, pooled in equimolar concentration, and purified prior to loading on an Illumina HiSeq 2500 modified to generate 300 bp paired-end reads. When the scientists compared microbial community members in cervicovaginal samples from those cases and controls, which were profiled with 16S ribosomal RNA gene sequencing, they saw seven bacterial taxa that appeared to be associated with spontaneous preterm birth, particularly in women with African-American ancestry. The team studied that association further using enzyme-linked immunosorbent assay (ELISA)-based immunological profiling, focused on host-derived anti-microbial peptides known as beta-defensin-2, that have previously been described in studies of the genital tract, both in healthy women and those suffering from bacterial infections.

The results indicated that the presence of Lactobacillus bacteria that are normally considered beneficial did not necessary coincide with diminished risk of spontaneous preterm birth. Instead, the data suggested that enhanced beta-defensin-2 levels in cervicovaginal samples typically coincided with decreased spontaneous preterm birth risk, while lower-than-usual levels of the protein tended to track with increased risk, even when high levels of bacteria belonging to Lactobacillus species were present. That beta-defensin-2 effect was especially pronounced in the African-American women, but was not significant when the team analyzed data for non-African-American women alone. Likewise, African-American women who delivered their infants at term also had increased beta-defensin-2 levels compared to non-African-American women with at-term deliveries.

The author concluded that higher vaginal levels of β-defensin-2 lowered the risk sPTB associated with cervicovaginal microbiota in an ethnicity-dependent manner. Surprisingly, even in Lactobacillus spp. dominated cervicovaginal microbiota, low β-defensin-2 was associated with increased risk of sPTB. Their findings hold promise for diagnostics to accurately identify women at risk for sPTB early in pregnancy. The study was published on March 21, 2019, in the journal Nature Communications.

Related Links:
University of Maryland School of Medicine

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more